Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Opthea ( (AU:OPT) ) has shared an announcement.
Opthea Limited announced the resignation of four directors following the failure of its Phase 3 trials to meet primary endpoints and a significant workforce reduction. The company is in negotiations with Development Funding Agreement investors to explore future options, amidst trading suspensions on ASX and Nasdaq due to financial uncertainties.
The most recent analyst rating on (AU:OPT) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited operates in the biotechnology industry, focusing on the development of therapies for treating eye diseases. The company is primarily engaged in advancing ophthalmology science through clinical trials and drug development.
YTD Price Performance: -25.93%
Average Trading Volume: 6,651,653
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
Learn more about OPT stock on TipRanks’ Stock Analysis page.